Cargando…
P1694: COST-EFFECTIVENESS OF AXICABTAGENE CILOLEUCEL VS. TISAGENLECLEUCEL FOR THE TREATMENT OF RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA: UPDATED SURVIVAL RESULTS FROM THE ZUMA-1 AND JULIET TRIALS
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10430029/ http://dx.doi.org/10.1097/01.HS9.0000973648.20075.6c |
| _version_ | 1785090855645741056 |
|---|---|
| author | Oluwole, Olalekan Ray, Markqayne Davies, Neil Bradford, Rory Jones, Calum Patel, Anik Locke, Frederick |
| author_facet | Oluwole, Olalekan Ray, Markqayne Davies, Neil Bradford, Rory Jones, Calum Patel, Anik Locke, Frederick |
| author_sort | Oluwole, Olalekan |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10430029 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-104300292023-08-17 P1694: COST-EFFECTIVENESS OF AXICABTAGENE CILOLEUCEL VS. TISAGENLECLEUCEL FOR THE TREATMENT OF RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA: UPDATED SURVIVAL RESULTS FROM THE ZUMA-1 AND JULIET TRIALS Oluwole, Olalekan Ray, Markqayne Davies, Neil Bradford, Rory Jones, Calum Patel, Anik Locke, Frederick Hemasphere Posters Lippincott Williams & Wilkins 2023-08-08 /pmc/articles/PMC10430029/ http://dx.doi.org/10.1097/01.HS9.0000973648.20075.6c Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Posters Oluwole, Olalekan Ray, Markqayne Davies, Neil Bradford, Rory Jones, Calum Patel, Anik Locke, Frederick P1694: COST-EFFECTIVENESS OF AXICABTAGENE CILOLEUCEL VS. TISAGENLECLEUCEL FOR THE TREATMENT OF RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA: UPDATED SURVIVAL RESULTS FROM THE ZUMA-1 AND JULIET TRIALS |
| title | P1694: COST-EFFECTIVENESS OF AXICABTAGENE CILOLEUCEL VS. TISAGENLECLEUCEL FOR THE TREATMENT OF RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA: UPDATED SURVIVAL RESULTS FROM THE ZUMA-1 AND JULIET TRIALS |
| title_full | P1694: COST-EFFECTIVENESS OF AXICABTAGENE CILOLEUCEL VS. TISAGENLECLEUCEL FOR THE TREATMENT OF RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA: UPDATED SURVIVAL RESULTS FROM THE ZUMA-1 AND JULIET TRIALS |
| title_fullStr | P1694: COST-EFFECTIVENESS OF AXICABTAGENE CILOLEUCEL VS. TISAGENLECLEUCEL FOR THE TREATMENT OF RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA: UPDATED SURVIVAL RESULTS FROM THE ZUMA-1 AND JULIET TRIALS |
| title_full_unstemmed | P1694: COST-EFFECTIVENESS OF AXICABTAGENE CILOLEUCEL VS. TISAGENLECLEUCEL FOR THE TREATMENT OF RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA: UPDATED SURVIVAL RESULTS FROM THE ZUMA-1 AND JULIET TRIALS |
| title_short | P1694: COST-EFFECTIVENESS OF AXICABTAGENE CILOLEUCEL VS. TISAGENLECLEUCEL FOR THE TREATMENT OF RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA: UPDATED SURVIVAL RESULTS FROM THE ZUMA-1 AND JULIET TRIALS |
| title_sort | p1694: cost-effectiveness of axicabtagene ciloleucel vs. tisagenlecleucel for the treatment of relapsed/refractory large b-cell lymphoma: updated survival results from the zuma-1 and juliet trials |
| topic | Posters |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10430029/ http://dx.doi.org/10.1097/01.HS9.0000973648.20075.6c |
| work_keys_str_mv | AT oluwoleolalekan p1694costeffectivenessofaxicabtageneciloleucelvstisagenlecleucelforthetreatmentofrelapsedrefractorylargebcelllymphomaupdatedsurvivalresultsfromthezuma1andjuliettrials AT raymarkqayne p1694costeffectivenessofaxicabtageneciloleucelvstisagenlecleucelforthetreatmentofrelapsedrefractorylargebcelllymphomaupdatedsurvivalresultsfromthezuma1andjuliettrials AT daviesneil p1694costeffectivenessofaxicabtageneciloleucelvstisagenlecleucelforthetreatmentofrelapsedrefractorylargebcelllymphomaupdatedsurvivalresultsfromthezuma1andjuliettrials AT bradfordrory p1694costeffectivenessofaxicabtageneciloleucelvstisagenlecleucelforthetreatmentofrelapsedrefractorylargebcelllymphomaupdatedsurvivalresultsfromthezuma1andjuliettrials AT jonescalum p1694costeffectivenessofaxicabtageneciloleucelvstisagenlecleucelforthetreatmentofrelapsedrefractorylargebcelllymphomaupdatedsurvivalresultsfromthezuma1andjuliettrials AT patelanik p1694costeffectivenessofaxicabtageneciloleucelvstisagenlecleucelforthetreatmentofrelapsedrefractorylargebcelllymphomaupdatedsurvivalresultsfromthezuma1andjuliettrials AT lockefrederick p1694costeffectivenessofaxicabtageneciloleucelvstisagenlecleucelforthetreatmentofrelapsedrefractorylargebcelllymphomaupdatedsurvivalresultsfromthezuma1andjuliettrials |